About this trial
The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.
Eligibility criteria
Qualifiers
abnormal uterine NK cell function;
have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;
have clear fertility desires;
normal ovarian function or with frozen embryos;
Disqualifiers
using progesterone receptor modulator;
chromosomal karyotype abnormalities in one spouse;
severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;
uncontrolled autoimmune diseases;
Trial design
Treatments tested in this trial
- autologous decidual-like NK cells
Treatment groups
Locations
1Sponsors and collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead sponsor
The University of Science and Technology of China
Collaborator